Overview

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Status:
Completed
Trial end date:
2015-01-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Collaborator:
Sanofi
Treatments:
Emollients